Literature DB >> 17594260

Do self-statements enhance the effectiveness of virtual reality exposure therapy? A comparative evaluation in acrophobia.

M Krijn1, P M G Emmelkamp, R P Olafsson, Martijn J Schuemie, Charles A P G van der Mast.   

Abstract

There is a clear need for more detailed analysis of the role of cognitive self-statements in virtual reality exposure therapy (VRET). To date, no research on this topic has been done. The primary aim of this study was to investigate whether coping self-statements would enhance the effectiveness of VRET. In a randomized crossover design, 26 patients with acrophobia (DSM-IV diagnosis of specific phobia) were randomly assigned to two sessions of VRET followed by two sessions of VRET plus coping self-statements, or the other way around: first two sessions of VRET plus coping self-statements followed by two sessions of VRET. Results showed that VRET, regardless of addition of coping self-statements, decreased anxiety of heights, decreased avoidance of height situations, and improved attitudes towards heights. However, at 6-month follow-up, most gains during treatment were not fully retained.

Entities:  

Mesh:

Year:  2007        PMID: 17594260     DOI: 10.1089/cpb.2006.9943

Source DB:  PubMed          Journal:  Cyberpsychol Behav        ISSN: 1094-9313


  2 in total

Review 1.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

2.  Virtual reality exposure using three-dimensional images for the treatment of social phobia.

Authors:  Cristiane M Gebara; Tito P de Barros-Neto; Leticia Gertsenchtein; Francisco Lotufo-Neto
Journal:  Braz J Psychiatry       Date:  2015-11-13       Impact factor: 2.697

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.